Authors

Amy L Bogue, Warunya Panmanee, Cameron T McDaniel, Joel E Mortensen, Edwin Kamau, Luis A Actis, Jay A Johannigman, Michael J Schurr, Latha Satish, Nalinikanth Kotagiri, Daniel J Hassett

Details

Published in PloS One, March 3, 2021,
Read the full publication at PloS One or at PMC NIH

Abstract

Multi-drug resistant (MDR) Acinetobacter baumannii (Ab) and Acinetobacter spp. present monumental global health challenges. These organisms represent model Gram-negative pathogens with known antibiotic resistance and biofilm-forming properties. Herein, a novel, nontoxic biocide, AB569, consisting of acidified nitrite (A-NO2-) and ethylenediaminetetraacetic acid (EDTA), demonstrated bactericidal activity against all Ab and Acinetobacter spp. strains, respectively. Average fractional inhibitory concentrations (FICs) of 0.25 mM EDTA plus 4 mM A-NO2- were observed across several clinical reference and multiple combat wound isolates from the Iraq/Afghanistan wars. Importantly, toxicity testing on human dermal fibroblasts ...

Authors

Daniel J. Hassett and Thomas J. Meyer

Details

Published in DNA and Cell Biology. September 4, 2020 – 1473-1477.
Read the abstract, or access the journal here

Abstract

Global antibiotic resistance, driven by intensive antibiotic exposure/abuse, constitutes a serious challenge to all health care, particularly in an era when new antimicrobial development has slowed to a trickle. Recently, we published work demonstrating the discovery and partial mechanism of action of a novel bactericidal agent that is effective against both gram-positive and gram-negative multidrug-resistant bacteria. This drug, called AB569, consists of acidified nitrite (A-NO₂⁻) and EDTA, of which there is no mechanism of resistance. Using both chemistry-, genetic-, and bioinformatics-based techniques, we first discovered that AB569 was able to generate bactericidal levels of nitric oxide (NO), while the EDTA component stabilized S-nitrosyl thiols, thereby furthering NO and downstream reactive ...

Authors

Jennifer J. Rahn^a,b,d, Xueqing Lun^a,b,d, Selina K. Jorch^c,e, Xiaoguang Hao^a,b,d, Chitra Venugopal^g, Parvez Vora^g, Bo Young Ahn^a,b,d, Liane Babes^a,b,d, Mana M. Alshehri^a,b,d,1, J. Gregory Cairncross^a,b,f, Sheila K. Singh^g, Paul Kubes^c,e, Donna L. Senger^a,b,d,∗∗, Stephen M. Robbins^a,b,d,∗

^a Arnie Charbonneau Cancer Institute, University of Calgary
^b Clark H. Smith Brain Tumour Centre, University of Calgary
^c Calvin, Phoebe & Joan Snyder Institute For Chronic Diseases, University of Calgary
^d Departments of Oncology, University of Calgary
^e Physiology and Pharmacology, University of Calgary
^f Clinical Neurosciences, University of Calgary
^g Department of Surgery, McMaster Children's Hospital, And McMaster Stem Cell and Cancer Research Institute, McMaster University

Details

Published in Biomaterials, Volume 252, 2020, 120105, ISSN 0142-9612,
Volume 252, September 2020, Available online 7 May 2020
Read the full article at Biomaterials / Elsevier

Abstract

Despite extensive molecular characterization, human glioblastoma remains a fatal disease with ...